Cingulate therapeutics llc

WebMar 10, 2024 · Cingulate plans to commence two CTx-1301 Phase 3 clinical studies in 2024: (1) a fixed-dose pediatric and adolescent safety and efficacy study, which will … WebMay 31, 2024 · Cingulate Therapeutics LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products …

SEC.gov HOME

WebCingulate. Manufacturing · Kansas, United States · <25 Employees . Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from freq uently diagnosed conditions … WebApr 3, 2024 · Determine whether Cingulate Therapeutics grew or shrank during the last recession. This is useful in estimating the financial strength and credit risk of the company. Compare how recession-proof Cingulate Therapeutics is relative to the industry overall. While a new recession may strike a particular industry, measuring the industry and … church welfare policy https://agriculturasafety.com

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public …

WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … WebFounders Craig Gilgallon, Matthew Brams, Raul Silva, Shane J Schaffer. Operating Status Active. Last Funding Type Venture - Series Unknown. … WebJul 10, 2024 · Cingulate Therapeutics, LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit ... church welfare policy pdf

Cingulate Therapeutics Kansas City KS - Facebook

Category:Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Results …

Tags:Cingulate therapeutics llc

Cingulate therapeutics llc

Cingulate Therapeutics Strengthens Leadership with Two New …

WebSep 14, 2024 · Prior to the closing of this IPO, the company will affect a “reorganization merger” in which Cingulate Inc. will acquire Cingulate Therapeutics LLC (CTx) through the merger of a wholly-owned ... WebCingulate. Manufacturing · Kansas, United States · &lt;25 Employees . Cingulate is a clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug …

Cingulate therapeutics llc

Did you know?

WebThis Joint Commercialization Agreement (this “Agreement”) is made on March 7 th 2024 (the “Effective Date”) by and between Indegene, Inc., a Delaware corporation having its place of business at Suite 104, 150 College Road W, Princeton, NJ 08540 (hereinafter referred to as “Indegene”) and Cingulate Therapeutics LLC, a Delaware ... WebJan 9, 2024 · Cingulate Therapeutics LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing the Company's innovative, precision ...

WebCingulate Therapeutics. Jan 2024 - Present4 years 4 months. Kansas City, Kansas. WebShane J. Schaffer founded Cingulate, Inc., Cingulate Works, Inc. and Cingulate Therapeutics LLC. Presently, Dr. Schaffer holds the position of Chairman &amp; Chief Executive Officer for Cingulate, Inc. and Chairman &amp; Chief Executive Officer of Cingulate Therapeutics LLC and Chairman &amp; Chief Executive Officer of Cingulate Works, Inc. …

WebSep 23, 2024 · EX-10.4 3 ex10-4.htm . Exhibit 10.4 . EMPLOYMENT AGREEMENT . This AGREEMENT (this “Agreement”) is made and effective as of this 23rd day of September, 2024 by and between CINGULATE THERAPEUTICS LLC, a Delaware Limited Liability Company, whose principal address is 1901 W. 47 th Place, 3 rd Floor, Kansas City, KS … WebFounder of Cingulate, Inc., Cingulate Works, Inc. and Cingulate Therapeutics LLC, Matthew N. Brams is an entrepreneur who currently is Chief Medical Officer &amp; Executive Vice President at Cingulate, Inc. and Director &amp; Chief Medical Officer at Cingulate Therapeutics LLC and Chief Medical Officer &amp; Executive Vice President at Cingulate …

WebOct 26, 2024 · Cingulate Therapeutics, LLC is a privately-held, clinical-stage, biopharmaceutical company focused on the development of new and innovative products …

WebExhibit 10.1 . AMENDMENT TO EMPLOYMENT AGREEMENT . This AMENDMENT is made and effective as of April 1, 2024 by and between CINGULATE THERAPEUTICS … dfeh changed nameWebJul 13, 2024 · Should You Buy or Sell Cingulate Stock? Get The Latest CING Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. ... dfeh certificate of completionWebSep 23, 2024 · EX-10.7 6 ex10-7.htm . Exhibit 10.7 . EMPLOYMENT AGREEMENT . This AGREEMENT (this “Agreement”) is made and effective as of this 23rd day of September, 2024 by and between CINGULATE THERAPEUTICS LLC, a Delaware Limited Liability Company, whose principal address is 1901 W. 47 th Place, 3 rd Floor, Kansas City, KS … dfeh cfra medical certification formWebCingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. dfeh case searchchurch welcome visitor signWebCingulate Inc. 1,061 followers. 2mo. Today we announce our Q3 2024 financial results and provided a clinical and business update, including updated study timelines for our lead … dfeh casesWebCingulate Therapeutics. Jan 2024 - Present4 years 4 months. Kansas City, Kansas. church welfare program